Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics Inc
(NQ:
PTGX
)
42.89
+0.60 (+1.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 14, 2022
The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!
Via
InvestorPlace
FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer
April 14, 2022
Protagonist Therapeutics Inc (NASDAQ: PTGX)
Via
Benzinga
Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech
March 16, 2022
Via
Benzinga
Protagonist Therapeutics's Return On Capital Employed Overview
March 03, 2022
Benzinga Pro data, Protagonist Therapeutics (NASDAQ:PTGX) reported Q4 sales of $8.62 million. Earnings fell to a loss of $36.91 million, resulting in a 9.18% decrease from last...
Via
Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
Analyst Ratings For Protagonist Therapeutics
October 12, 2021
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate
December 03, 2021
Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the...
Via
Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
December 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases...
Via
Benzinga
What 9 Analyst Ratings Have To Say About Protagonist Therapeutics
November 15, 2021
Over the past 3 months, 9 analysts have published their opinion on Protagonist Therapeutics (NASDAQ:
Via
Benzinga
Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month
November 08, 2021
Following huge swings over the last two months, the biotech stock is now up 67% year to date.
Via
The Motley Fool
Exposures
Product Safety
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List
November 01, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger
October 25, 2021
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A...
Via
Benzinga
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
October 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...
Via
Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
October 18, 2021
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....
Via
Benzinga
Exposures
Product Safety
What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
October 13, 2021
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
October 13, 2021
MKM Partners raised the price target on Continental Resources, Inc. (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 12, 2021
Gainers NRX Pharmaceuticals (NASDAQ:NRXP...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
October 12, 2021
Evercore ISI Group raised Lear Corporation (NYSE:
Via
Benzinga
46 Biggest Movers From Yesterday
October 12, 2021
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’...
Via
Benzinga
Exposures
Product Safety
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
October 11, 2021
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
October 11, 2021
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is...
Via
Benzinga
Where Protagonist Therapeutics Stands With Analysts
October 11, 2021
Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observ...
Via
Benzinga
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
October 11, 2021
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
28 Stocks Moving In Monday's Mid-Day Session
October 11, 2021
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...
Via
Benzinga
Exposures
Product Safety
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
October 11, 2021
Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies.
Via
InvestorPlace
Exposures
Product Safety
Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug
October 11, 2021
Protagonist Therapeutics can now restart dosing patients in its rusfertide studies.
Via
Investor's Business Daily
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.